The survival benefit gained from adding chemotherapy to supportive care has been reaffirmed for patients with non-small-cell lung cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1653, 2008-01, pp. : 19-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vandetanib has value in non-small-cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1544, 2006-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Advances in chemotherapy in advanced non-small-cell lung cancer

By Maione Paolo   Rossi Antonio   Sacco Paola Claudia   Bareschino Maria Anna   Schettino Clorinda   Gridelli Cesare  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 18, 2010-12 ,pp. : 2997-3007

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?

By Giovannetti Elisa   Toffalorio Francesca   De Pas Tommaso   Peters Godefridus J  

Pharmacogenomics, Vol. 13, Iss. 9, 2012-07 ,pp. : 1073-1086

Future Medicine

Access to resources Recommend Favorite

Pemetrexed prolongs survival in patients with malignant pleural mesothelioma or non-small-cell lung cancer

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 21, Iss. 10, 2005-10 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

Treatment with irinotecan plus cisplatin has a similar survival benefit to etoposide plus cisplatin in patients with extensive-stage small cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1540, 2006-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite